Detection of 11 germline inactivating TP53 mutations and absence of TP63 andHCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome

Editor—The Li-Fraumeni syndrome (LFS) represents one of the most devastating genetic predispositions to cancers. This rare syndrome, affecting children and young adults, is characterised by a wide spectrum of early onset malignancies including bone and soft tissue sarcomas, brain tumours, adrenocortical tumours, and premenopausal breast cancers.1 LFS was initially defined using stringent criteria2: (1) a proband with a sarcoma diagnosed before the age of 45, (2) a first degree relative with cancer before the age of 45, and (3) another first or second degree relative with either a sarcoma diagnosed at any age or any cancer diagnosed under the age of 45. Subsequently, Birch et al 3 defined Li-Fraumeni-like (LFL) syndrome as a proband with any childhood tumour or sarcoma, brain tumour, or adrenocortical tumour under 45 years, plus a first or second degree relative with a typical LFS tumour at any age and another first or second degree relative with any cancer under the age of 60. Eeles4 proposed more relaxed criteria for LFL: a clustering of two typical LFS tumours in subjects who are first or second degree relatives at any age. Since the original reports of germline mutations of the tumour suppressor gene TP53 in LFS,5 6 numerous studies have shown that germline TP53 mutations can be detected in approximately 70% of LFS families and 20% of LFL families,1 suggesting the possible involvement of other genes in LFS. This hypothesis was recently confirmed by the detection, in one LFS family and one family suggestive of LFS, of germline mutations of hCHK2 , the human homologue of the Saccharomyces cerevisiae RAD53 gene, located on chromosome 22q12.7 8 hCHK2 encodes a kinase, which is able to phosphorylate, in response to DNA damage, the Cdc25C phosphatase involved in the G2 checkpoint …

[1]  R. Eeles.  Germline mutations in the TP53 gene. , 1995, Cancer surveys.

[2]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[3]  R. Iggo,et al.  Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast , 1998, Oncogene.

[4]  R. Cotton,et al.  Mutation detection : a practical approach , 1998 .

[5]  Michael Bamshad,et al.  Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome , 1999, Cell.

[6]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[7]  M. Augustin,et al.  Cloning and chromosomal mapping of the human p53-related KET gene to Chromosome 3q27 and its murine homolog Ket to mouse Chromosome 16 , 1998, Mammalian Genome.

[8]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[9]  S. Kato,et al.  Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer , 1999, Oncogene.

[10]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[11]  S. Elledge,et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.

[12]  C. Harris,et al.  Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. , 1999, Cancer research.

[13]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[14]  R. Iggo,et al.  A rapid PCR fidelity assay. , 1994, Nucleic acids research.

[15]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[16]  R. Eeles,et al.  Screening hCHK2 for mutations. , 2000, Science.

[17]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[18]  P. Chappuis,et al.  A simple p53 functional assay for screening cell lines, blood, and tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Carr,et al.  Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway , 1999, Oncogene.

[20]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[21]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[22]  J. Fraumeni,et al.  Multiple primary cancers in families with Li-Fraumeni syndrome. , 1998, Journal of the National Cancer Institute.

[23]  S. Kato,et al.  The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. , 1999, Cancer research.

[24]  D. Evans,et al.  Li-Fraumeni syndrome--a molecular and clinical review. , 1997, British Journal of Cancer.